Plain-English translation of NCT05672147 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing CD33-CAR T cell therapy, a personalized immune cell treatment for people with acute myeloid leukemia (AML) that has returned or stopped responding to standard chemotherapy. Researchers take your immune cells, modify them in the lab to better recognize and attack your leukemia cells, and then give them back to you. The study will measure how well the treatment works and whether it is safe.
Many patients with relapsed or refractory acute myeloid leukemia have limited options because their cancer either comes back after initial treatment or never responds to it in the first place. This medication represents a new approach using your own immune system to fight the disease when standard treatments have not worked.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy for 3–5 days to prepare your body (called lymphodepletion). On day 0, you receive an infusion of the modified immune cells through an IV. After that, you will be closely monitored for safety and effectiveness. If your leukemia persists more than 28 days after the first infusion and you have not had serious side effects, you may be offered a second dose of the treatment. Throughout the study, you will have regular blood tests and bone marrow checks to see how well the treatment is working.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States